Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m

LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually. The post Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m appeared first on PE Hub .

We haven't written up this one. PE Hub has the full story — the link below goes straight to it.

Read the original at pehub.com →

More in Health & Medicine

More from Tuesday 18 August →